Skip to search formSkip to main contentSkip to account menu

AG 024322

Known as: AG-024322, AG024322 
A cyclin-dependent kinase (CDK) inhibitor with antineoplastic activity. AG-024322 selectively inhibits cyclin-dependent kinases (particularly CDK1,2… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
Abstract 2979: Combined cdk1 and PARP inhibition results in tumor regression in a KrasG12D p53L/L murine lung adenocarcinoma model
Kras is one of the most commonly mutated oncogenes in non-small cell lung cancer (NSCLC), and targeted therapies are not… 
2008
2008
Toxicity and toxicokinetics of the cyclin-dependent kinase inhibitor AG-024322 in cynomolgus monkeys following intravenous infusion
PurposeCyclin-dependent kinases (CDKs) play a significant role in the control of cell-cycle progression and exhibit aberrant… 
2005
2005
AG-024322 is a potent and selective multi-targeted CDK inhibitor with broad spectrum anti-proliferative activity
4415 Uncontrolled cell proliferation is the hallmark of cancer, and is typically manifested by a de-regulation of the cell… 
2005
2005
AG-024322 is a multi-targeted CDK inhibitor with potent antitumor activity in vivo
4413 Deregulated cyclin-dependent kinase (CDK) activity is characterized by uncontrolled cell cycle progression, which is a… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)